{"preliminary_commentary":{"by_channel":{"x_thread":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"PICC","nct_id":"NCT03926338","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=picc-nct03926338. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PICC","arms":[{"description":"Neoadjuvant toripalimab with or without celecoxib for 6 cycles","label":"PICC-1 exploratory cohort","type":"EXPERIMENTAL"},{"description":"Neoadjuvant toripalimab with or without celecoxib for 12 cycles","label":"PICC-2 cohort","type":"EXPERIMENTAL"},{"description":"Toripalimab plus celecoxib as neoadjuvant or definitive therapy","label":"PICC-3 cohort","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-04-01","type":"ESTIMATED"},"conditions":["Colorectal Cancer","Mismatch Repair-deficient (dMMR)","Microsatellite Instability-high (MSI-H)","Neoadjuvant Therapy"],"enrollment":{"count":270,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Neoadjuvant toripalimab plus celecoxib for 6 cycles","otherNames":["Toripalimab","Celecoxib"],"type":"DRUG"},{"name":"Neoadjuvant toripalimab monotherapy for 6 cycles","otherNames":["Toripalimab"],"type":"DRUG"},{"name":"Neoadjuvant toripalimab plus celecoxib for 12 cycles","otherNames":["Toripalimab","Celecoxib"],"type":"DRUG"},{"name":"Neoadjuvant toripalimab monotherapy for 12 cycles","otherNames":["Toripalimab"],"type":"DRUG"},{"name":"Toripalimab plus celecoxib as neoadjuvant or definitive therapy","otherNames":["Toripalimab","Celecoxib"],"type":"DRUG"}],"last_update":"2025-11-20","lead_sponsor":"Sun Yat-sen University","official_title":"Neoadjuvant PD-1 Blockade by Toripalimab With or Without Celecoxib in Mismatch-repair Deficient or Microsatellite Instability-high Locally Advanced Colorectal Cancer (PICC)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-04-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Pathological complete response (pCR) rates (PICC-1 and PICC-2 cohorts)","timeFrame":"1 year"},{"measure":"Event-free survival (EFS) (PICC-3 cohort)","timeFrame":"3 years"}],"references":[{"citation":"Hu H, Shen X, Li Y, Zhou J, Liu P, Zhang J, Hou Y, Wang X, Deng J, Zheng Z, Li J, Lan P, Wu X, Kang L, Huang M, He Z, He X, Yang Z, Huang L, Wang H, Wang H, Luo S, Chen D, Xie X, Zhang Y, Zhai X, Li S, Li W, Hu J, Yang T, Wang C, Deng W, Huang Y, Cao W, Li F, Shi L, Ling L, Deng Y. Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2026 Aug;27(8):1020-1030. doi: 10.1016/S1470-2045(26)00220-2. Epub 2026 Jul 1.","pmid":"42385761","type":"DERIVED"},{"citation":"Cao W, Hu H, Li J, Wu Q, Shi L, Li B, Zhou J, Wang X, Chen J, Wang C, Wang H, Deng W, Huang Y, Deng Y. China special issue on gastrointestinal tumors-Radiological features of pathological complete response in mismatch repair deficient colorectal cancer after neoadjuvant PD-1 blockade: A post hoc analysis of the PICC phase II trial. Int J Cancer. 2023 Dec 1;153(11):1894-1903. doi: 10.1002/ijc.34647. Epub 2023 Jul 6.","pmid":"37409565","type":"DERIVED"},{"citation":"Hu H, Kang L, Zhang J, Wu Z, Wang H, Huang M, Lan P, Wu X, Wang C, Cao W, Hu J, Huang Y, Huang L, Wang H, Shi L, Cai Y, Shen C, Ling J, Xie X, Cai Y, He X, Dou R, Zhou J, Ma T, Zhang X, Luo S, Deng W, Ling L, Liu H, Deng Y. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):38-48. doi: 10.1016/S2468-1253(21)00348-4. Epub 2021 Oct 22.","pmid":"34688374","type":"DERIVED"},{"citation":"Wang D, Cabalag CS, Clemons NJ, DuBois RN. Cyclooxygenases and Prostaglandins in Tumor Immunology and Microenvironment of Gastrointestinal Cancer. Gastroenterology. 2021 Dec;161(6):1813-1829. doi: 10.1053/j.gastro.2021.09.059. Epub 2021 Oct 2.","pmid":"34606846","type":"DERIVED"}],"start_date":{"date":"2019-05-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT03926338"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/picc-nct03926338"}